Erratum

Online summary

Correction to: Karagianis J, Rosenbluth M, Tohen M, et al. Reviewing CATIE for clinicians: balancing benefit and risk using evidence-based medicine tools. Curr Med Res Opin 2007;23:2551–57.

This article refers to:

Reviewing CATIE for clinicians:balancing benefit and risk using evidence-based medicine tools

Correction to: Karagianis J, Rosenbluth M, Tohen M, et al. Reviewing CATIE for clinicians: balancing benefit and risk using evidence-based medicine tools. Curr Med Res Opin 2007;23:2551–57

Recently an erratum on the original CATIE paper1 was published in NEJM2 with a corrected risk ratio for hospitalization of 0.17 per person-year of treatment for the olanzapine group, as compared with risk ratios of 0.30 to 0.44 in the other groups. The original version of the paper stated the risk ratio was 0.29 for olanzapine as compared with risk ratios ranging from 0.45 to 0.66 in the other groups. This erratum affects some of the calculations that went into our paper, but it does not affect the conclusions of our paper3. The number needed to treat (NNT) and likelihood of being helped or harmed (LHH) comparison tables that follow reflect the corrected calculations. There are no changes to footnotes.

Table 4 should now be:

Table 4.  Prevention of hospitalization events for exacerbation of schizophrenia based on 1-year risk ratios (hospitalizations per total person year of exposure).

Drug Comparison	AR	NNT (95% CI)	NNT Rounded Up	AR × 100
Olanzapine vs. Quetiapine	0.26	3.8 (2.9 to 5.7)	4	26
Olanzapine vs. Risperidone	0.13	7.7 (4.8 to 19.2)	8	13
Olanzapine vs. Ziprasidone	0.22	4.4 (3.0 to 8.5)	5	22
Olanzapine vs. Perphenazine	0.16	6.2 (4.0 to 13.5)	7	16

Table 6 should now be:

Table 6.  Events expected when treating 100 patients with olanzapine rather than a comparator over 18 months.

Outcome: Olanzapine vs …	Quetiapine	Risperidone	Ziprasidone	Perphenazine
All-Cause Discontinuation	18 fewer*	10 fewer*	16 fewer*	11 fewer*
Hospitalized Patients	9 fewer*	4 fewer	7 fewer *	4 fewer
Hospitalization Events in 12 Months (extrapolated to 18 months)†	26* (39) fewer	13* (19) fewer	22* (33) fewer	16* (24) fewer
Weight Gain >7%	14 more*	16 more*	23 more*	18 more*
New Prescription for Glucose-Lowering Agent or Insulin	2 more	2 more	2 more	2 more
New Prescription for Statin	1 more	2 more	4 more*	2 more

Table 7 should now be:

Table 7.  LHHs for olanzapine vs. other antipsychotics.

Olanzapine vs…	Risperidone			Quetiapine			Perphenazine			Ziprasidone
	NNH	NNT	LHH	NNH	NNT	LHH	NNH	NNT	LLH	NNH	NNT	LHH
WG > 7%/HEA	6.3	7.7	0.82	7.2	3.8	1.89	5.6	6.2	0.90	4.4	4.4	1.00
DWGM/HEA	13.4	7.7	1.74	17.6	3.8	4.63	12.4	6.2	2.00	16.7	4.4	3.80

Old text (bottom left of page 2555): Further comparisons of benefits and risks using LHHs are shown in Table 7. In each case, the LHH favors olanzapine because the ratio is greater than 1.

New proposed text: Further comparisons of benefits and risks using LHHs are shown in Table 7. In 5 of 8 comparisons the LHH favors olanzapine because the ratio is greater than 1.

Old text (top right of page 2556): For example, if you treat three patients with olanzapine rather than quetiapine you may expect to prevent 1 hospital admission event.

New proposed text: For example, if you treat four patients with olanzapine rather than quetiapine you may expect to prevent 1 hospital admission event.

In the same paragraph, 37 is now replaced by 26, and 55 is now replaced by 39.